Aszites, spontan bakterielle Peritonitis, hepatorenales ... - DGVS

241 Ricart E, Soriano G, Novella MT et al. Amoxicillin-clavulanic acid versus
cefotaxime in the therapy of bacterial infections in cirrhotic patients.
J Hepatol 2000; 32: 596–602
242 Acevedo JC, Fernandez J, Castro M et al. Current efficacy of recommended
empirical antibiotic therapy in patients with cirrhosis and bacterial
infection (Abstract). J Hepatol 2009; 50: S5
243 Castellote J, Ariza X, Girbau A et al. Risk factors to cefotaxime-resistant
spontaneous bacterial peritonitis (Abstract). J Hepatol 2010; 52: S69
244 Angeloni S, Leboffe C, Parente A et al. Efficacy of current guidelines for
the treatment of spontaneous bacterial peritonitis in the clinical
practice. World J Gastroenterol 2008; 14: 2757–2762
245 Yakar T, Guclu M, Serin E et al. A recent evaluation of empirical cephalosporin
treatment and antibiotic resistance of changing bacterial
profiles in spontaneous bacterial peritonitis. Dig Dis Sci 2010; 55:
1149–1154
246 Castellote J, Ariza X, Girbau A et al. Antibiotic-resistant bacteria in
spontaneous bacterial peritonitis. Is it time to change? (Abstract).
J Hepatol 2010; 52: S69
247 Cheong HS, Kang CI, Lee JA et al. Clinical significance and outcome of
nosocomial acquisition of spontaneous bacterial peritonitis in patients
with liver cirrhosis. Clin Infect Dis 2009; 48: 1230–1236
248 Dupeyron C, Mangeney N, Sedrati L et al. Rapid emergence of quinolone
resistance in cirrhotic patients treated with norfloxacin to prevent
spontaneous bacterial peritonitis. Antimicrob Agents Chemother
1994; 38: 340–344
249 Dupeyron C, Campillo SB, Mangeney N et al. Carriage of Staphylococcus
aureus and of gram-negative bacilli resistant to third-generation
cephalosporins in cirrhotic patients: a prospective assessment of
hospital-acquired infections. Infect Control Hosp Epidemiol 2001;
22: 427–432
250 Campillo B, Dupeyron C, Richardet JP et al. Epidemiology of severe hospital-acquired
infections in patients with liver cirrhosis: effect of
long-term administration of norfloxacin. Clin Infect Dis 1998; 26:
1066–1070
251 Campillo B, Dupeyron C, Richardet JP. Epidemiology of hospital-acquired
infections in cirrhotic patients: effect of carriage of methicillin-resistant
Staphylococcus aureus and influence of previous antibiotic
therapy and norfloxacin prophylaxis. Epidemiol Infect 2001;
127: 443–450
252 Song KH, Jeon JH, Park WB et al. Clinical outcomes of spontaneous
bacterial peritonitis due to extended-spectrum beta-lactamaseproducing
Escherichia coli and Klebsiella species: a retrospective
matched case-control study. BMC Infect Dis 2009; 9: 41
253 Umgelter A, Reindl W, Miedaner M et al. Failure of current antibiotic
first-line regimens and mortality in hospitalized patients with spontaneous
bacterial peritonitis. Infection 2009; 37: 2–8
254 Chavez-Tapia NC, Soares-Weiser K, Brezis M et al. Antibiotics for spontaneous
bacterial peritonitis in cirrhotic patients. Cochrane Database
Syst Rev 2009: CD002232
255 Chen TA, Lo GH, Lai KH et al. Single daily amikacin versus cefotaxime
in the short-course treatment of spontaneous bacterial peritonitis in
cirrhotics. World J Gastroenterol 2005; 11: 6823–6827
256 Rastegar LA, Umrani G, Dehbashi N et al. Evaluation of the therapeutic
effect of pefloxacin in comparison with ampicillin and gentamicin in
cirrhotic patients with spontaneous bacterial peritonitis. Hepatogastroenterology
1998; 45: 783–785
257 Antillon MR, Runyon BA. Effect of marked peripheral leukocytosis on
the leukocyte count in ascites. Arch Intern Med 1991; 151: 509–510
258 Ljubicic N, Spajic D, Vrkljan MM et al. The value of ascitic fluid polymorphonuclear
cell count determination during therapy of spontaneous
bacterial peritonitis in patients with liver cirrhosis. Hepatogastroenterology
2000; 47: 1360–1363
259 Runyon BA, Hoefs JC. Spontaneous vs secondary bacterial peritonitis.
Differentiation by response of ascitic fluid neutrophil count to antimicrobial
therapy. Arch Intern Med 1986; 146: 1563–1565
260 Fong TL, Akriviadis EA, Runyon BA et al. Polymorphonuclear cell count
response and duration of antibiotic therapy in spontaneous bacterial
peritonitis. Hepatology 1989; 9: 423–426
261 Runyon BA, McHutchison JG, Antillon MR et al. Short-course versus
long-course antibiotic treatment of spontaneous bacterial peritonitis.
A randomized controlled study of 100 patients. Gastroenterology
1991; 100: 1737–1742
262 Bauer TM, Follo A, Navasa M et al. Daily norfloxacin is more effective
than weekly rufloxacin in prevention of spontaneous bacterial peritonitis
recurrence. Dig Dis Sci 2002; 47: 1356–1361
Leitlinie 777
263 Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of
refractory ascites and hepatorenal syndrome in cirrhosis. International
Ascites Club. Hepatology 1996; 23: 164–176
264 Salerno F, Gerbes A, Gines P et al. Diagnosis, prevention and treatment
of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310–1318
265 Solanki P, Chawla A, Garg R et al. Beneficial effects of terlipressin in
hepatorenal syndrome: a prospective, randomized placebo-controlled
clinical trial. J Gastroenterol Hepatol 2003; 18: 152–156
266 Sanyal AJ, Boyer T, Garcia-Tsao G et al. A randomized, prospective,
double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal
syndrome. Gastroenterology 2008; 134: 1360–1368
267 Martin-Llahi M, Pepin MN, Guevara M et al. Terlipressin and albumin
vs albumin in patients with cirrhosis and hepatorenal syndrome: a
randomized study. Gastroenterology 2008; 134: 1352–1359
268 Neri S, Pulvirenti D, Malaguarnera M et al. Terlipressin and albumin in
patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci
2008; 53: 830–835
269 Ortega R, Gines P, Uriz J et al. Terlipressin therapy with and without
albumin for patients with hepatorenal syndrome: results of a prospective,
nonrandomized study. Hepatology 2002; 36: 941–948
270 Saner F, Kavuk I, Lang H et al. Terlipressin and gelafundin: safe therapy
of hepatorenal syndrome. Eur J Med Res 2004; 9: 78–82
271 Dart AB, Mutter TC, Ruth CA et al. Hydroxyethyl starch (HES) versus
other fluid therapies: effects on kidney function. Cochrane Database
Syst Rev 2010: CD007594
272 Fabrizi F, Dixit V, Messa P et al. Terlipressin for hepatorenal syndrome:
A meta-analysis of randomized trials. Int J Artif Organs 2009; 32:
133–140
273 Gluud LL, Christensen K, Christensen E et al. Systematic review of randomized
trials on vasoconstrictor drugs for hepatorenal syndrome.
Hepatology 2010; 51: 576–584
274 Sagi SV, Mittal S, Kasturi KS et al. Terlipressin therapy for reversal of
type 1 hepatorenal syndrome: a meta-analysis of randomized controlled
trials. J Gastroenterol Hepatol 2010; 25: 880–885
275 Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome:
continuous infusion as an alternative to i. v. bolus administration.
Gastroenterology 2009; 137: 1179; author reply 1179 – 1181
276 Hadengue A, Gadano A, Moreau R et al. Beneficial effects of the 2-day
administration of terlipressin in patients with cirrhosis and hepatorenal
syndrome. J Hepatol 1998; 29: 565–570
277 Gerbes AL, Gulberg V, Waggershauser T et al. Renal effects of transjugular
intrahepatic portosystemic shunt in cirrhosis: comparison of
patients with ascites, with refractory ascites, or without ascites. Hepatology
1998; 28: 683–688
278 Guevara M, Gines P, Bandi JC et al. Transjugular intrahepatic portosystemic
shunt in hepatorenal syndrome: effects on renal function and
vasoactive systems. Hepatology 1998; 28: 416–422
279 Brensing KA, Textor J, Perz J et al. Long term outcome after transjugular
intrahepatic portosystemic stent-shunt in non-transplant cirrhotics
with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288–
295
280 Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and
TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Hepatology 2004; 40: 55–64
281 Testino G, Ferro C, Sumberaz A et al. Type-2 hepatorenal syndrome
and refractory ascites: role of transjugular intrahepatic portosystemic
stent-shunt in eighteen patients with advanced cirrhosis awaiting
orthotopic liver transplantation. Hepatogastroenterology 2003; 50:
1753–1755
282 Witzke O, Baumann M, Patschan D et al. Which patients benefit from
hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol
2004; 19: 1369–1373
283 Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome
with extracorporeal albumin dialysis MARS: results of a prospective,
randomized, controlled clinical trial. Liver Transpl 2000; 6:
277–286
284 Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system
is ineffective in the management of type 1 hepatorenal syndrome
in patients with cirrhosis with ascites who have failed vasoconstrictor
treatment. Gut 2010; 59: 381–386
285 Bannares R, Nevens F, Larsen FS et al. Extracorporeal liver support
with the molecular adsorbent recirculating system (MARS) in patients
with acute-on-chronic liver failure (AOCLF). The RELIEF trail
(Abstract). J Hepatol 2010; 52: S459–S460
Gerbes AL et al. S3-Leitlinie „Aszites, spontan… Z Gastroenterol 2011; 49: 749 –779
Heruntergeladen von: Thieme Verlagsgruppe. Urheberrechtlich geschützt.